Cochlear Limited share price hits $180: Is it still a buy?

The Cochlear Limited (ASX:COH) share price has had a cracking run recently.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price hit an all-time high of $180.88 this morning, taking their yearly gains to 43%. Cochlear shares are up 158% over the past 10 years, according to Google Finance.

Cochlear's great run can be attributed in part to its business model, which involves heavy investment in research & development – Cochlear is widely recognised as a global leading in hearing aids. By developing advanced new products, Cochlear profits on the original sale, as well as on servicing the hearing aid throughout its useful life. With a dependent customer, Cochlear is also first in line to sell new products to the customer, resulting in long customer lifespans and significant value generation for the company.

However, while the company's profits have been growing strongly in recent times, a significant amount of that benefit was due to a weaker Australian dollar. Many of Cochlear's sales are in foreign currency, so a weaker Australian dollar effectively boosts profits.

Currently, Cochlear controls an estimated 70% of the hearing market globally, making it the dominant player and suggesting that further room for claiming market share here could be limited. However, Cochlear serves just 5% of the estimated people worldwide that suffer from hearing loss, which suggests that a huge number of people remain under-served, likely due to reasons of price and/or inability to access Cochlear's services.

This provides a decent tailwind, which could see Cochlear continue to grow strongly for many years in the future. However, today's share price of $180 reflects more than 40x this year's forecast earnings for Cochlear. Given that the forecast implies only 5% profit growth compared to last year, I believe that Cochlear's quality and bright future are already more than priced in.

Motley Fool contributor Sean O'Neill has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »